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ABSTRACT
Objective: The main objective of the present study is the systematic development of solid dispersions of Candesartan cilexetil by solvent evaporation 
method to enhance the solubility and bioavailability.
Methods: In the present study, 18 formulations of SD were prepared with 1:1 and 1:3 ratios of drug: Carrier and with and without surfactant. There 
was a significant improvement in the rate of drug release from all 20 SD and the formulation (SD16) comprising Candesartan: Containing Soluplus 
(1:3 ratio of drug: Soluplus with 2% sodium lauryl sulfate as a surfactant) by a solvent evaporation process.
Results: Final optimized design SD16 contained maximum drug content of 99.08%. In in vitro dissolution studies, it shows greater dissolution 
rate, that is, 99.7±4.2% associated through additional designs and pure drug. The drug was compatible with all the excipients as per the Fourier 
transform infrared spectroscopy. From powder X-ray diffraction and by (scanning electron microscope) studies, it was evident that crystalline form of 
Candesartan has been converted into amorphous form within SD design.
Conclusion: From these studies, we can accomplish SD are one of the greatest favorable formulation for Candesartan cilexetil for enhancing the 
solubility and bioavailability of poorly water-soluble drugs in the effective group of hypertension and other cardiac problems.
Keywords: Candesartan cilexetil, Hypertension, Solid dispersions, Soluplus, Poloxamer, Kolliwax.
INTRODUCTION
Candesartan is a common drug used for the treatment of hypertension 
and heart failure. Delivery of candesartan is difficult due to its low 
aqueous solubility, efflux through intestinal p-glycoprotein and 
vulnerability to enzymatic degradation in the small intestine [1]. Hence, 
various formulations are continuously researched and developed of 
which lipid-based systems are most widely accepted [2]. Low oral 
solubility and bioavailability are the major hurdles for designing delivery 
systems with improved pharmacokinetic profiles and therapeutic 
responses [3]. Drugs belonging to BCS Class II and IV have inspired 
formulators for the expansion of drug delivery technologies to overcome 
the effort in their solubilization by biochemical or mechanical alteration 
of the environment surrounding drug substance/physically altering 
macromolecular characteristics of aggregated drug particles [4].
To control hypertension Thiazide diuretics, angiotensin-converting 
enzyme inhibitors, β-blockers, calcium antagonists, and AT1 antagonists 
are employed mostly to prevent organ damage and reduce the mortality 
rate. However, most of these undertake extensive first-pass metabolism, 
frequent administration and have varied bioavailability [5]. The most 
possible method for increasing dissolution with the help of a water-soluble 
carrier is to reduce the particle size and thereby increase the surface 
area of absorption. Several approaches can be utilized to obtain solid 
dispersions (SD) that enhance solubility and bioavailability such as fusion, 
fusion dissolution, solvent removal, and spray drying [6]. The term SD 
refers to two different components, hydrophilic matrix, and hydrophobic 
drug. Hydrophilic carriers include povidone (polyvinylpyrrolidone 
[PVP]), polyethylene glycols (6000, 8000, etc.), and many more [7]. Nature 
of the solvent and the rate and temperature of evaporation are critical 
factors that can affect the final formulation [8]. This method is unique that 
thermal decay of drugs can be prevented as low temperature is required 
for the removal of the organic solvents [9].
The aim of this study is to design and evaluate various formulations of 
Candesartan SD prepared using different polymer ratios so as to increase 
the overall solubility and bioavailability of the final formulation.
MATERIALS AND METHODS
Materials
Candesartan cilexetil pure drug was gifted from Aurobindo Pharma 
Ltd, Hyderabad, India. Poloxamer 407 and PEG 8000 obtained from 
BASF, Mumbai. Kolliwax GMS was obtained from Signet Chemical Corp. 
Pvt. Ltd, Mumbai. Soluplus was gifted from BASF, Germany. PVP K-30 
was gifted from Dow Chemicals, USA. All other chemicals used are of 
analytical grade.
Preliminary solubility studies of Candesartan cilexetil
Solubility measurements of Candesartan cilexetil performed according 
to a published method reported by Higuchi and Connors in 1965 [10]. 
Excess amount of Candesartan cilexetil existed added to 25 ml aqueous 
solution of water-soluble carriers such as PEG8000, Soluplus, Kolliwax 
GMS II, Poloxamer 407, and PVPK-30 screw-capped bottles. Samples 
are shaken for 24 h at room temperature. Subsequently, suspensions 
are filtered through Whatman filter paper no 1. Filtered solutions are 
diluted up to the mark with methanol. Diluted solutions of Candesartan 
cilexetil analyzed at UV 257 nm.
Preparation of Candesartan cilexetil SD by solvent evaporation 
method
The calculated amount of Candesartan cilexetil and the employed 
polymers (Soluplus, Kolliwax GMS, Poloxamer 407, PEG 8000, and 
PVPK-30) in different drug-polymer ratios (1:1 and 1:3) besides sodium 
lauryl sulfate (SLS) as surfactant (0 or 2%) (as shown in Table 1) 
are weighed and mixed together in a porcelain dish. 20 different 
formulations prepared by a solvent evaporation method. Drug and 
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polymer mixtures were dissolved in the least amount of methanol as a 
common solvent. The solvent was evaporated in an oven at temperature 
50°C till complete evaporation. SD thus prepared were pulverized in a 
mortar and sieved. The fraction of powder that passed through 45 μm 
sieve was stored in a desiccator and used for further investigations.
Evaluation of Candesartan cilexetil SD
SD obtained from the above method were tested for their percentage 
practical yield, drug content, and in vitro drug release studies.
Percentage practical yield
Percentage of practical yield was calculated to know about percent yield 
or efficiency of the method so as to help in the selection of a suitable 
method of production [11].
Drug content
SD equivalent to 16 mg Candesartan cilexetil is weighed accurately 
and dissolved in 100 ml of methanol. Solution is filtered, diluted with 
a suitable solvent and drug content is analyzed at λmax 257 nm against 
blank by UV spectrometer [12].
In vitro dissolution study of SD
USP dissolution test type II apparatus (Electrolab TDT- 06 N, India) is 
used. Amount of samples equivalent to 16 mg drug was dispersed into a 
dissolution vessel containing 900 mL phosphate buffer pH 6.5 containing 
0.75% Tween 20 at 37°C and stirred at 50 rpm. Samples are withdrawn 
periodically, filtered and replaced with fresh dissolution medium. After 
filtration through 0.45 μm microfilter, the concentration of Candesartan 
cilexetil is determined spectrophotometrically at λ max 257 nm [13].
Characterization
Fourier transform infrared (FTIR) studies
Using Shimadzu FTIR-8700 spectrophotometer, potassium bromide disc 
method is employed. Pure drug, physical mixtures, and SD are studied. 
Powdered samples are intimately mixed with dry powdered potassium 
bromide. This mixture was then compressed into a transparent disc under 
high pressure using special dies. Disc is placed in IR spectrophotometer 
using a sample holder, and then the spectrum is recorded [14].
Powder X-ray diffraction (p-XRD)
X-ray powder diffraction patterns were recorded on an X-ray powder 
diffraction system (Shimadzu, Japan) using copper target, a voltage of 
40 Kv and a current of 30 mA. The scanning was done over 2_ range of 
5–60° [15].
Scanning electron microscope (SEM) studies
Surface morphology of layered sample was inspected using SEM 
(Hitachi, Japan). Small amount of powder was manually dispersed 
onto a carbon tab (double adhesive carbon coated tape) adhered to 
an aluminum stub. These sample stubs were coated with a thin layer 
(30Å) of gold by employing POLARON-E 3000 sputter coater. Samples 
are examined by SEM and photographed under various magnifications 
with direct data capture images onto a computer [16].
Stability studies
Systematized SD were placed inside sealed 40cc HDPE container with 
child-resistant cap under controlled temperature environment inside 
stability chamber (Thermo Lab, India) with a relative humidity of 
75%±5% RH and temperature 40°C±2°C for stability studies. Samples 
were removed after 1, 2, and 3 months and evaluated for percentage 
drug content and in vitro dissolution studies and compared with those 
SDs tested immediately after preparation [17].
RESULTS AND DISCUSSION
Preliminary solubility studies Candesartan cilexetil
Preliminary solubility studies were carried out to select suitable water-
soluble carriers for the preparation of SD. Pure drug solubility was 
found to be 0.417 mg/ml. From this study, drug and Soluplus in ratio 
of 1:1 shown highest drug solubility of about 1.69±0.05 mg/ml, almost 
4-fold increase paralleled to that of pure drug. For all the water-soluble 
carriers used in preliminary solubility studies, Avicel PH 102, Colloidal 
Silicone dioxide (Aerosil 200), and urea have shown low solubility when 
compared with other carriers and are not included in the preparation of 







Poloxamer (g) Kolliwax 
GMS (g)





SD 1 0.16 0.16 - - - - 0 Qs
SD 2 0.16 0.16 - - - - 2 Qs
SD 3 0.16 0.48 - - - - 0 Qs
SD 4 0.16 0.48 - - - - 2 Qs
SD 5 0.16 - 0.16 - - - 0 Qs
SD 6 0.16 - 0.16 - - - 2 Qs
SD 7 0.16 - 0.48 - - - 0 Qs
SD 8 0.16 - 0.48 - - - 2 Qs
SD 9 0.16 - - 0.16 - - 0 Qs
SD 10 0.16 - - 0.16 - - 2 Qs
SD 11 0.16 - - 0.48 - - 0 Qs
SD 12 0.16 - - 0.48 - - 2 Qs
SD 13 0.16 - - - 0.16 - 0 Qs
SD 14 0.16 - - - 0.16 - 2 Qs
SD 15 0.16 - - - 0.48 - 0 Qs
SD 16 0.16 - - - 0.48 - 2 Qs
SD 17 0.16 - - - - 0.16 0 Qs
SD 18 0.16 - - - - 0.16 2 Qs
SD 19 0.16 - - - - 0.48 0 Qs
SD 20 0.16 - - - - 0.48 2 Qs
SD: Solid dispersions, PVP: Polyvinylpyrrolidone, SLS: Sodium lauryl sulfate
Table 2: Preliminary solubility studies Candesartan cilexetil in 
different polymers





Drug+Avicel PH 102 0.99±0.04
Drug+Soluplus 1.69±0.05
Drug+PEG 8000 1.22±0.07
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Candesartan cilexetil SD. The graphical representation solubility studies 
of Candesartan cilexetil physical mixtures are shown in Fig. 1 and Table 2.
Preparation of Candesartan cilexetil SD
Candesartan cilexetil SD were prepared and shown in Fig. 2.
Evaluation parameters
Solubility studies of Candesartan cilexetil SD
Different formulations of Candesartan cilexetil SD were prepared 
using solvent evaporation method with their respective carriers. After 
preparation, SD solubility analysis was carried out. Formulation (SD16) 
with Soluplus in the ratio of 1:3 and SLS showed the highest solubility, 
that is, 4.599±0.07 mg/ml, almost 11-fold compared to that pure drug 
(pure drug solubility is 0.417±0.04 mg/ml). Results were tabulated in 
Table 3 and the graphical representation is shown in Fig. 3.
Percent practical yield and drug content
Results of percent practical yield for all formulations of SD were found to 
be in the range of 83.88–99.28%; results are shown in Table 4. Maximum 
yield found to be 99.28% in formulation SD16. The drug content in 
prepared SD found to be in the range of 86.33–99.08%. Maximum 
percent drug content, that is, 99.08% found in formulation SD16.
In vitro dissolution studies
Drug release data obtained for formulations SD1-SD20 are tabulated in 
Tables 5-7, respectively. They show a cumulative percent drug released 
as a function of time for all formulations. In vitro studies reveal that there 
Fig. 1: Solubility studies of Candesartan cilexetil physical mixture
Fig. 2: Candesartan cilexetil solid dispersions
Table 3: Solubility studies of Candesartan cilexetil solid 
dispersions (SD) prepared by a solvent evaporation method
Formulation code Solubility (mg/ml)*





















Table 4: Percent practical yield and drug content for 
Candesartan cilexetil SD
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Table 5: In vitro dissolution profile of pure drug and different formulations of Candesartan cilexetil SD1-SD8
Time (minutes) Cumulative % drug release
Pure drug SD1 SD2 SD3 SD4 SD5 SD6 SD7 SD8
0 0 0 0 0 0 0 0 0 0
5 3.11±0.43 20.6±2.9 22.6±2.9 26.8±2.0 30.3±2.5 23.3±3.4 26.4±2.9 25.5±1.3 21.5±1.3
10 4.38±0.12 31.7±3.9 32.7±3.9 30.3±2.9 36.9±1.5 31.2±1.4 33.8±2.3 31.0±2.4 31.0±2.4
20 7.01±0.36 50.8±2.0 44.8±2.0 46.5±3.3 48.5±2.7 43.3±2.3 39.5±1.6 35.5±3.3 32.5±3.3
30 12.12±0.73 61.4±1.4 58.4±1.4 55.5±3.8 58.2±2.6 59.1±2.9 45.8±1.8 39.1±2.6 41.1±2.6
45 17.09±0.40 70.7±3.8 69.7±3.8 65.5±1.9 68.5±2.2 63.2±1.4 59.5±1.7 46.0±2.4 45.0±2.4
60 21.22±0.80 81.4±2.2 78.4±2.2 72.9±3.3 79.3±2.9 77.5±3.6 69.9±1.8 66.2±4.3 68.2±1.5
90 25.55±0.64 83.6±1.7 85.6±2.7 88.4±3.1 91.5±2.8 81.8±3.3 84.2±1.2 88.8±3.1 90.9±3.4
SD: Solid dispersions
Table 6: In vitro dissolution profile of different formulations of Candesartan cilexetil SD9-SD14
Time in min Cumulative % drug release
SD9 SD10 SD11 SD12 SD13 SD14
0 0 0 0 0 0 0
5 26.6±2.9 25.2±3.7 26.6±2.9 23.6±2.9 26.6±2.9 23.4±2.9
10 36.7±3.9 32.6±1.9 41.7±3.9 33.7±3.9 36.7±3.9 39.8±2.3
20 58.8±2.0 44.6±2.5 53.8±2.0 48.8±2.0 49.8±2.0 51.5±1.6
30 63.4±1.4 56.8±0.55 65.4±1.4 63.4±1.35 58.4±1.4 61.8±1.8
45 77.7±0.8 68.5±0.13 73.7±3.7 72.7±3.6 67.7±3.8 69.5±1.7
60 81.5±2.2 79.9±2.5 83.5±2.9 84.4±2.2 77.4±2.2 79.9±1.8
90 83.22±1.7 84.1±3.8 86.6±1.7 88.8±1.7 89.6±2.7 91.3±1.2
SD: Solid dispersions
Table 7: In vitro dissolution profile of different formulations of Candesartan cilexetil SD15-SD20
Time in min Cumulative % drug release
SD15 SD16 SD17 SD18 SD19 SD20
0 0 0 0 0 0 0
5 21.5±1.3 40.1±2.3 23.5±1.3 25.5±1.3 27.5±1.3 29.5±1.3
10 31.0±2.4 59.2±2.8 33.0±2.4 35.0±2.4 37.0±2.4 39.0±2.4
20 55.5±3.3 68.5±2.2 39.5±3.3 41.5±3.3 45.5±3.3 48.5±3.3
30 68.1±2.6 77.2±2.3 43.1±2.6 49.1±2.6 51.1±2.6 53.1±2.6
45 73.0±2.4 89.4±3.0 56.0±0.4 58.0±2.2 61.0±2.12 65.0±2.01
60 84.2±4.3 96.6±1.6 61.2±0.03 65.2±0.25 68.2±1.2 69.2±4.3
90 94.8±3.4 99.7±4.2 72.1±1.12 73.9±1.01 75.2±1.22 79.7±1.44
SD: Solid dispersions
Fig. 3: Solubility studies of Candesartan cilexetil solid dispersion
is marked an increase in the dissolution rate of Candesartan cilexetil 
from all the SD when compared to pure Candesartan cilexetil itself. 
From the in vitro drug release profile, it can be seen that formulation 
SD16 containing Soluplus (1:3 ratio of drug: Soluplus with surfactant) 
shows higher dissolution rate, that is, 99.7±4.2% compared with other 
formulations. This may be attributed to the increase in drug wettability, 
conversion to amorphous form and solubilization of the drug due to 
the hydrophilic carrier. The graphical representation of SD of SD1-SD8, 
SD9-SD14, and SD15-SD20 with the pure drug is depicted in Figs. 4-6, 
respectively.
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Fig. 4: In vitro dissolution profile of the pure drug and different formulations of Candesartan cilexetil solid dispersions (SD1-SD8)
Fig. 5: In vitro dissolution profile of different formulations of Candesartan cilexetil solid dispersions (SD9-SD14)
Fig. 6: In vitro dissolution profile of different formulations of Candesartan cilexetil solid dispersions (SD15-SD20)
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Fig. 7: Fourier transform infrared spectrum of Candesartan cilexetil pure drug
Fig. 8: Fourier transform infrared spectrum of Soluplus
Fig. 9: Fourier transform infrared spectrum of sodium lauryl sulfate
Characterization
FTIR studies
FTIR studies pure drug Candesartan cilexetil, Soluplus, SLS, its physical 
mixtures and SD conducted (Figs. 7-11). FTIR spectra of Candesartan 
cilexetil showed characteristic peaks at 2932 cm−1 due to C-H slight 
bend, 1712 cm−1 due to C=O stretching, 1115 cm−1 due to CO stretching, 
1275 cm−1 due to C-N stretching, and 3610 cm−1 due to N-H bend. IR 
spectra of physical mixture displayed superimposition Candesartan 
cilexetil and Soluplus peaks with decreased peak intensity. IR spectra 
optimized formulation of SD showed a peak corresponding to C-H 
Candesartan cilexetil shifted from 2932 cm−1 to 2865 cm1, which suggests 
the presence of hydrogen bonding, resulting in an increase in solubility. 
Other peaks related to C=O, C-O, C-N, and N-H remained unchanged.
X-ray diffraction patterns
XRD studies for Candesartan cilexetil SD carried out to find out whether 
SD of various drug-polymer ratios are crystalline or amorphous. The 
presence of numerous distinct peaks in the XRD spectrum of pure 
Candesartan cilexetil indicates that Candesartan cilexetil present as 
a crystalline material (Fig. 12). On the other hand, the spectrum of 
optimized formulation SD16 SD characterized by complete absence of 
any diffraction peak, which is characteristic of an amorphous compound 
(Fig. 13). Enhancement in the dissolution rate of the drug from drug-
Soluplus-SLS SD is ascribed to marked reduction in crystallinity of the 
drug.
SEM studies
SEM photographs for pure drug and optimized formulation SD16 are 
shown in Figs. 14 and 15, respectively. Drug crystals seemed to be 
smooth-surfaced, irregular in shape and size. In the case of SD, it is 
difficult to distinguish the presence of drug crystals. Drug surface in 
SD seems to be more porous in nature. SD appeared as uniform and 
homogeneously mixed mass with a wrinkled surface. Drug crystals 
appeared to be incorporated into particles of the polymers. SD looked 
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Fig. 10: Fourier transform infrared spectrum of Candesartan cilexetil physical mixture
Fig. 11: Fourier transform infrared spectrum of Candesartan cilexetil optimized formulation SD16
Fig. 12: X-ray diffractograms of Candesartan cilexetil pure drug
like a matrix particle. Results could be attributed to dispersion of the 
drug in molten mass of polymer.
Stability studies
Optimized formulation (SD16) was selected for stability studies on 
the basis of high cumulative percent drug release. Stability studies 
are conducted for drug content and in vitro drug release studies for 
3 months at accelerated stability conditions according to the ICH 
guidelines. The optimized formulation is stable during 3 months period. 
From these results, it is concluded that optimized formulation (SD16) is 
stable and retained its original properties with minor differences. The 
results are summarized in Table 8.
CONCLUSION
From solubility and in vitro studies, it can be revealed that there is 
marked increase in dissolution rate of Candesartan cilexetil from all 
SD when compared to pure Candesartan cilexetil itself. It can be seen 
that optimized formulation SD16 containing Soluplus (1:3 ratio of 
drug: Soluplus with surfactant) shows higher dissolution rate, that 
is, 99.7±4.2% when compared with other formulations. This may be 
attributed to the increase in drug wettability, conversion to amorphous 
form and solubilization of drug due to the hydrophilic carrier. FTIR results 
confirm the molecular binding of Candesartan cilexetil with Soluplus. 
DSC and XRD studies also confirm the molecular amalgamation of the 
drug in an amorphous state with the polymers. From these studies, we 
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Fig. 13: X-ray diffractograms of Candesartan cilexetil optimized formulation SD16
Fig. 14: Pure drug of Candesartan
Fig. 15: Candesartan optimized formulation SD16S
Table 8: Evaluation parameters of optimized 
formulation (SD16) stored at 40±2°C/75±5%rh
Retest time for optimized 
formulation (days)
% Drug content In vitro drug 
release (%)
0 day 99.08 99.70
30 days  98.39 98.55
60 days 97.65 97.45
90 days 96.05 96.15
SD: Solid dispersions
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